Abstract:Advanced identification of the gene mutations causing epilepsy syndromes is expected to translate into faster diagnosis and more effective treatment of these conditions. Over the last 5 years, approximately 40 clinical trials on the treatment of genetic epilepsies have been conducted. As a result, some medications that are not regular antiseizure drugs (e.g., soticlestat, fenfluramine, or ganaxolone) have been introduced to the treatment of drug-resistant seizures in Dravet, Lennox-Gastaut, maternally inherited chromosome 15q11.2-q13.1 duplication (Dup 15q) syndromes, and protocadherin 19 (PCDH 19)-clusterig epilepsy. And although the effects of soticlestat, fenfluramine, and ganaxolone are described as promising, they do not significantly affect the course of the mentioned epilepsy syndromes. Importantly, each of these syndromes is related to mutations in several genes. On the other hand, several mutations can occur within one gene, and different gene variants may be manifested in different disease phenotypes. This complex pattern of inheritance contributes to rather poor genotype-phenotype correlations. Hence, the detection of a specific mutation is not synonymous with a precise diagnosis of a specific syndrome. Bearing in mind that seizures develop as a consequence of the predominance of excitatory over inhibitory processes, it seems reasonable that mutations in genes encoding sodium and potassium channels, as well as glutamatergic and gamma-aminobutyric (GABA) receptors, play a role in the pathogenesis of epilepsy. In some cases, different pathogenic variants of the same gene can result in opposite functional effects, determining the effectiveness of therapy with certain medications. For instance, seizures related to gain-of-function (GoF) mutations in genes encoding sodium channels can be successfully treated with sodium channel blockers. On the contrary, the same drugs may aggravate seizures related to loss-of-function (LoF) variants of the same genes. Hence, knowledge of gene mutation-treatment response relationships facilitates more favorable selection of drugs for anticonvulsant therapy.

Advances in the studies on the molecular and genetic aspects of epilepsy]

Clinical and Molecular Analysis of Epilepsy-Related Genes in Patients with Dravet Syndrome

Variable epilepsy phenotypes associated with heterozygous mutation in the SCN9A gene: report of two cases

GABAA receptor epilepsy mutations

The Molecular Biology of Genetic-Based Epilepsies

Voltage-gated potassium channels and genetic epilepsy

Potassium channels and epilepsy

Recent Progress in Identifying Genetic and Epigenetic Contributions to Epilepsy

Voltage-Gated Channels As Causative Agents for Epilepsies

Genetic and epigenetic mechanisms of epilepsy: a review

Advance in Molecular Genetic Research on Generalized Epilepsies

[Advance in Genetic Study for Idiopathic Generalized Epilepsy].

Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies

Pharmacogenetic and Case-Control Study on Potassium Channel Related Gene Variants and Genetic Generalized Epilepsy

Unraveling the genetic basis of epilepsy: Recent advances and implications for diagnosis and treatment

Genetic Background of Epilepsy and Antiepileptic Treatments

Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies.

[Research on Genes Susceptible to Childhood Absence Epilepsy].

Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy

Advances of research in ion channels in idiopathic epilepsy

Genotypic and phenotypic characteristics of sodium channel-associated epilepsy in Chinese population